Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.
W A Denny , W R Wilson , H H Lee , K M Thompson
The British journal of cancer. Supplement 27 43 -47
30
1996
Sequence selectivity, cross-linking efficiency and cytotoxicity of DNA-targeted 4-anilinoquinoline aniline mustards.
W A Denny , S McClean , L P Wakelin , Mark Searcey
Anti-cancer Drug Design 14 ( 3) 187 -204
15
1999
Nitro reduction as an electronic switch for bioreductive drug activation.
B G Siim , W A Denny , W R Wilson
Oncology Research 9 357 -369
43
1997
Interaction of the antitumour antibiotic streptonigrin with DNA and oligonucleotides
Margaret Harding , Georgina Long , J Y Fan , W A Denny
Anti-cancer Drug Design 12 ( 6) 453 -472
7
1997
Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
H H Lee , W A Denny , W R Wilson
Anti-cancer Drug Design 14 ( 6) 487 -497
8
1999
Aniline mustard analogues of the DNA-intercalating agent amsacrine: DNA interaction and biological activity
W A Denny , B C Baguley , K K Valu , J Y Fan
Anti-cancer Drug Design 12 ( 3) 181 -203
22
1997
New directions in the design and evaluation of anti-cancer drugs.
W A Denny
Drug design and delivery 3 ( 2) 99 -124
7
1988
Molecular modelling of DNA-antitumour drug intercalation interactions: correlation of structural and energetic features with biological properties for a series of phenylquinoline-8-carboxamide compounds.
S Neidle , T C Jenkins , A J Beveridge , W A Denny
Molecular Pharmacology 35 ( 5) 720 -728
6
1989
Structure−activity relationships of 9-anilinoacridines as inhibitors of human DNA topoisomerase II
W A Denny , S A Gamage , D P Figgitt , R K Ralph
Anti-cancer Drug Design 9 ( 3) 199 -208
8
1994
Structure-activity relationships for substituted 9-oxo-9,10-dihydroacridine-4-acetic acids: analogues of the colon tumour active agent xanthenone-4-acetic acid
W A Denny , B C Baguley , G W Rewcastle , S A Gamage
Anti-cancer Drug Design 7 ( 5) 403 -414
14
1992
Interaction of the antitumour antibiotic luzopeptin with the hexanucleotide duplex d(5′-GCATGC)2. One-dimensional and two-dimensional n.m.r. studies
M S Searle , J G Hall , W A Denny , L P Wakelin
Biochemical Journal 259 ( 2) 433 -441
19
1989
Radiosensitization of E. coli B/r by 9-anilinoacridines.
P B Roberts , W A Denny , B F Cain
British Journal of Cancer 40 ( 4) 641 -648
8
1979
Selective toxicity of nitracrine to hypoxic mammalian cells
W R Wilson , W A Denny , S J Twigden , B C Baguley
British Journal of Cancer 49 ( 2) 215 -223
71
1984
An indoline-derived compound that markedly reduces mouse body weight.
M Tercel , R N Marnane , M A Tatnell , R J Stevenson
International Journal of Obesity 37 ( 5) 685 -692
1
2013
Uptake of acridinecarboxamide derivatives by L1210 cells.
E Ciesielska , K Studzian , G Bazylak , E Pastwa
Acta Biochimica Polonica 45 ( 4) 1047 -1051
1998
The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).
D C Singleton , D Li , S Y Bai , S P Syddall
Cancer Gene Therapy 14 ( 12) 953 -967
38
2007
DNA-intercalating ligands as anti-cancer drugs: prospects for future design.
Denny Wa
Anti-cancer Drug Design 4 ( 4) 241 -263
165
1989
Synthesis, DNA binding interactions and biological activity of bis platinum (II) complexes of N,N,N',N'-tetrakis(2-aminoethyl)diamines
Denny Wa , Baguley Bc , Palmer Bd , Craik Dj
Anti-cancer Drug Design 7 ( 5) 385 -401
15
1992
Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
Denny Wa , Wilson Wr , Anderson Rf , Tercel M
Anti-cancer Drug Design 13 ( 6) 663 -685
40
1998
'Minimal' DNA-intercalating agents as anti-tumour drugs: 2-styrylquinoline analogues of amsacrine.
Denny Wa , Baguley Bc , Atwell Gj
Anti-cancer Drug Design 2 ( 3) 263 -270
13
1987